The First Evaluation of a Novel Vitamin K Antagonist, Tecarfarin (ATI-5923), in Patients With Atrial Fibrillation-Reference-Cited by-同舟云学术

The First Evaluation of a Novel Vitamin K Antagonist, Tecarfarin (ATI-5923), in Patients With Atrial Fibrillation

Published:2009-09-22 Issue:12 Volume:120 Page:1029-1035
ISSN:0009-7322
Container-title:Circulation
language:en
Short-container-title:Circulation

Author:

Ellis David J.¹,Usman Mohammed Haris¹,Milner Peter G.¹,Canafax Daniel M.¹,Ezekowitz Michael D.¹

Affiliation:

1. From Lankenau Institute for Medical Research, Wynnewood, Pa (M.H.U.U., M.D.E.); Mercy Catholic Medical Center, Darby, Pa (M.H.U.U.); Section of Vascular Medicine, University of Pennsylvania Health System, Philadelphia (M.H.U.U.); and ARYx Therapeutics Inc, Fremont, Calif (D.E., P.M., D.C.).

Publisher

Ovid Technologies (Wolters Kluwer Health)

Subject

Physiology (medical),Cardiology and Cardiovascular Medicine

Reference38 articles.

1. Bleeding Complications With Warfarin Use

2. The Effect of Low-Dose Warfarin on the Risk of Stroke in Patients with Nonrheumatic Atrial Fibrillation

3. Canadian atrial fibrillation anticoaguiation (CAFA) study

Cited by 71 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Antithrombotic Therapy for Mechanical Circulatory Support: Time to Throw the Baby (Warfarin) Out With the Bathwater (Aspirin)?;Circulation: Heart Failure;2024-08

2. Antithrombotic Strategies With Left Ventricular Assist Devices;Journal of Cardiac Failure;2024-08

3. Antithrombotic therapy after heart valve intervention: review of mechanisms, evidence and current guidance;Heart;2023-07-12

4. Safety and Tolerability of Tecarfarin (ATI-5923) in Healthy Chinese Volunteers: Multiple Oral Dose-Escalation Phase I Trial;American Journal of Cardiovascular Drugs;2023-01

5. From multi-target anticoagulants to DOACs, and intrinsic coagulation factor inhibitors;Blood Reviews;2020-01